Cargando…

Effect of Ambrisentan Therapy on the Expression of Endothelin Receptor, Endothelial Nitric Oxide Synthase and NADPH Oxidase 4 in Monocrotaline-induced Pulmonary Arterial Hypertension Rat Model

BACKGROUND AND OBJECTIVES: Elevated endothelin (ET)-1 level is strongly correlated with the pathogenesis of pulmonary arterial hypertension (PAH). Expression level of nicotinamide adenine dinucleotide phosphate oxidase (NOX) 4 is increased in the PAH patients. Ambrisentan, a selective endothelin rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hyeryon, Yeom, Arim, Kim, Kwan Chang, Hong, Young Mi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713827/ https://www.ncbi.nlm.nih.gov/pubmed/31165592 http://dx.doi.org/10.4070/kcj.2019.0006

Ejemplares similares

Change of voltage-gated potassium channel 1.7 expressions in monocrotaline-induced pulmonary arterial hypertension rat model
por: Lee, Hyeryon, et al.
Publicado: (2018)

Gene Expression of Endothelin-1 and Endothelin Receptor A on Monocrotaline-Induced Pulmonary Hypertension in Rats After Bosentan Treatment
por: Lim, Kyoung Ah, et al.
Publicado: (2010)

Gene Expressions of Nitric Oxide Synthase and Matrix Metalloproteinase-2 in Monocrotaline-Induced Pulmonary Hypertension in Rats After Bosentan Treatment
por: Koo, Hee Sun, et al.
Publicado: (2011)

Effect of Small Hairpin RNA Targeting Endothelin-Converting Enzyme-1 in Monocrotaline-Induced Pulmonary Hypertensive Rats
por: Son, Jae Sung, et al.
Publicado: (2012)

Ambrisentan for the treatment of pulmonary arterial hypertension
por: Casserly, Brian, et al.
Publicado: (2009)

Role of Endothelin-1 in Right Atrial Arrhythmogenesis in Rabbits with Monocrotaline-Induced Pulmonary Arterial Hypertension
por: Lu, Yen-Yu, et al.
Publicado: (2022)

Role of endothelin receptor A and NADPH oxidase in vascular abnormalities
por: Dai, De-Zai, et al.
Publicado: (2010)

A review of pulmonary arterial hypertension: role of ambrisentan
por: Barst, Robyn J
Publicado: (2007)

Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
por: Elshaboury, Soha M, et al.
Publicado: (2013)

Transforming growth factor-β inhibition and endothelin receptor blockade in rats with monocrotaline-induced pulmonary hypertension
por: Megalou, Aikaterini J., et al.
Publicado: (2012)

Metformin prevents the development of monocrotaline-induced pulmonary hypertension by decreasing serum levels of big endothelin-1
por: Yoshida, Tomohiko, et al.
Publicado: (2020)

Farnesyl diphosphate synthase regulated endothelial proliferation and autophagy during rat pulmonary arterial hypertension induced by monocrotaline
por: Jin, Tingting, et al.
Publicado: (2022)

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension
por: Safdar, Zeenat
Publicado: (2011)

Open label study of ambrisentan in patients with exercise pulmonary hypertension
por: Segrera, Sergio A., et al.
Publicado: (2017)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

The Effect of Umbilical Cord Blood Derived Mesenchymal Stem Cells in Monocrotaline-induced Pulmonary Artery Hypertension Rats
por: Lee, Hyeryon, et al.
Publicado: (2015)

Expression of Endothelin-1 and Endothelial Nitric Oxide Synthase in Normal and Preeclamptic Placentae
por: Khaing, Aung, et al.
Publicado: (2022)

Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension
por: Zhang, Zeyu, et al.
Publicado: (2022)

The effect of sildenafil on right ventricular remodeling in a rat model of monocrotaline-induced right ventricular failure
por: Bae, Hyun Kyung, et al.
Publicado: (2016)

Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats
por: Serizawa, Ken-ichi, et al.
Publicado: (2011)

Nicorandil Attenuates Monocrotaline-Induced Vascular Endothelial Damage and Pulmonary Arterial Hypertension
por: Sahara, Makoto, et al.
Publicado: (2012)

Granulocyte colony-stimulating factor attenuates monocrotaline-induced pulmonary hypertension by upregulating endothelial progenitor cells via the nitric oxide system
por: LIU, JUN-FENG, et al.
Publicado: (2013)

Genetic variance in Nitric Oxide Synthase and Endothelin Genes among children with and without Endothelial Dysfunction
por: Chatsuriyawong, Siriporn, et al.
Publicado: (2013)

Regulation of Smooth Muscle Cell Proliferation by NADPH Oxidases in Pulmonary Hypertension
por: Huetsch, John C., et al.
Publicado: (2019)

Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis
por: Kappes, Lucy, et al.
Publicado: (2020)

Monocrotaline Induces Endothelial Injury and Pulmonary Hypertension by Targeting the Extracellular Calcium–Sensing Receptor
por: Xiao, Rui, et al.
Publicado: (2017)

Pentaerythritol Tetranitrate In Vivo Treatment Improves Oxidative Stress and Vascular Dysfunction by Suppression of Endothelin-1 Signaling in Monocrotaline-Induced Pulmonary Hypertension
por: Steven, Sebastian, et al.
Publicado: (2017)

Sensitivity to endothelin-1 is decreased in isolated livers of endothelial constitutive nitric oxide synthase knockout mice
por: De Gottardi, Andrea, et al.
Publicado: (2006)

Endothelin-1 but not Endothelial Nitric Oxide Synthase Gene Polymorphism is Associated with Sickle Cell Disease in Africa
por: Thakur, Tanya J, et al.
Publicado: (2014)

Pulmonary Arterial Hypertension and Endothelial Dysfunction Is Linked to NADPH Oxidase-Derived Superoxide Formation in Venous Thrombosis and Pulmonary Embolism in Mice
por: Brandt, Moritz, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model
por: Lee, Yun Hee, et al.
Publicado: (2011)

Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats
por: Polonio, Igor Bastos, et al.
Publicado: (2014)

Arginase Inhibition Reverses Monocrotaline-Induced Pulmonary Hypertension
por: Jung, Christian, et al.
Publicado: (2017)

Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats
por: Sadowska, Olga, et al.
Publicado: (2020)

Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition
por: Wu, Yonghui, et al.
Publicado: (2021)

Polydatin Glycosides Improve Monocrotaline-Induced Pulmonary Hypertension Injury by Inhibiting Endothelial-To-Mesenchymal Transition
por: Chen, Xing, et al.
Publicado: (2022)

Apoptosis and Inflammation Associated Gene Expressions in Monocrotaline-Induced Pulmonary Hypertensive Rats after Bosentan Treatment
por: Hong, Young Mi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_frk9otcljokucb3q8af7rb7n0o